

John P M Finberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8776508/publications.pdf>

Version: 2024-02-01

20
papers

1,737
citations

687363

13
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

2695
citing authors

#	ARTICLE	IF	CITATIONS
1	Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease. <i>Molecular Psychiatry</i> , 2021, 26, 2626-2632.	7.9	36
2	Static Magnetic Field Exposure In Vivo Enhances the Generation of New Doublecortin-expressing Cells in the Sub-ventricular Zone and Neocortex of Adult Rats. <i>Neuroscience</i> , 2020, 425, 217-234.	2.3	8
3	The discovery and development of rasagiline as a new anti-Parkinson medication. <i>Journal of Neural Transmission</i> , 2020, 127, 125-130.	2.8	8
4	Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 433-448.	2.8	65
5	Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human α -Synuclein: Comparison with Dopaminergic and Serotonergic Denervation. <i>ACS Chemical Neuroscience</i> , 2018, 9, 291-297.	3.5	5
6	Sensor Array for Detection of Early Stage Parkinson's Disease before Medication. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2548-2553.	3.5	25
7	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. <i>ACS Nano</i> , 2017, 11, 112-125.	14.6	386
8	Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. <i>Frontiers in Pharmacology</i> , 2016, 7, 340.	3.5	269
9	Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates. <i>Neuroscience Bulletin</i> , 2015, 31, 705-713.	2.9	4
10	Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. , 2014, 143, 133-152.		197
11	Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. <i>Neuropharmacology</i> , 2013, 65, 48-57.	4.1	21
12	Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase. <i>European Journal of Pharmacology</i> , 2012, 683, 226-230.	3.5	4
13	Selective inhibitors of monoamine oxidase type B and the "cheese effect". <i>International Review of Neurobiology</i> , 2011, 100, 169-190.	2.0	87
14	Modulation of excessive neuronal activity by fibroblasts: Potential use in treatment of Parkinson's disease. <i>Restorative Neurology and Neuroscience</i> , 2010, 28, 803-815.	0.7	3
15	Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. <i>European Journal of Pharmacology</i> , 2003, 472, 173-177.	3.5	25
16	Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. <i>Neuropharmacology</i> , 2002, 43, 1110-1118.	4.1	66
17	Rasagiline [N -propargyl- R (+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. <i>British Journal of Pharmacology</i> , 2001, 132, 500-506.	5.4	321
18	Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. <i>British Journal of Pharmacology</i> , 1999, 126, 997-1002.	5.4	44

#	ARTICLE	IF	CITATIONS
19	Effect of Long-Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo. <i>Journal of Neurochemistry</i> , 1996, 67, 1532-1539.	3.9	122
20	Inhibition of nerve stimulation-induced vasodilatation in corpora cavernosa of the pithed rat by blockade of nitric oxide synthase. <i>British Journal of Pharmacology</i> , 1993, 108, 1038-1042.	5.4	41